Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.3 USD | +1.44% | +3.43% | -37.78% |
Sales 2024 * | 6.79M 8.63M | Sales 2025 * | 75.82M 96.38M | Capitalization | 773M 983M |
---|---|---|---|---|---|
Net income 2024 * | -100M -127M | Net income 2025 * | -69M -87.71M | EV / Sales 2024 * | 86.8 x |
Net cash position 2024 * | 184M 234M | Net cash position 2025 * | 146M 186M | EV / Sales 2025 * | 8.26 x |
P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-29.8
x | Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | +1.00% | ||
1 week | +0.50% | ||
Current month | +0.50% | ||
1 month | -17.76% | ||
3 months | -25.26% | ||
6 months | -17.03% | ||
Current year | -38.98% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 12.38 | +2.06% | 281 454 |
24-06-07 | 12.13 | +1.00% | 769,829 |
24-06-06 | 12.01 | -1.07% | 534,233 |
24-06-05 | 12.14 | +0.33% | 1,453,070 |
24-06-04 | 12.1 | +1.17% | 1,109,634 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.98% | 984M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- VRNA Stock